Karyopharm Therapeutics (KPTI) RBC Capital Markets Global Healthcare Conference 2026 summary

Key clinical data and upcoming presentations

• Phase III SENTRY trial for selinexor plus ruxolitinib in frontline myelofibrosis showed rapid, deep, and sustained SVR35, meaningful TSS improvements, and a promising overall survival signal with a hazard ratio of 0.43 and nominal p-value of 0.0222 at a median 12-month follow-up.

• No new safety signals identified; full data to be presented publicly for the first time at ASCO as a late-breaker.

• Trial designed for ongoing follow-up of overall survival and other endpoints until maturity, with continued monitoring planned.

• Confidence in SVR35 as a surrogate for long-term outcomes, supported by literature and internal data.

Regulatory and guideline engagement

• Expecting clarity on next steps with the FDA within the next one to two quarters, with stable regulatory relationships and prior agreement on trial design.

• Positive feedback from opinion leaders regarding NCCN guideline inclusion; ASCO data and upcoming peer-reviewed publication expected to support this process.

• NCCN listing could enable broad payer coverage and rapid adoption, especially in high unmet need areas like myelofibrosis.

Market opportunity and adoption

• Initial adoption expected in academic centers and among key MF specialists, with broader uptake as NCCN guidelines are updated.

• Endometrial cancer and myelofibrosis represent multi-billion dollar opportunities, with most patients treated in the community setting.

• Commercial infrastructure and payer support programs are in place to facilitate launches in new indications.